期刊文献+

罗格列酮对糖尿病大鼠肾脏病理变化的影响

在线阅读 下载PDF
导出
摘要 目的观察罗格列酮对糖尿病大鼠肾损害的保护作用并探讨其作用机制。方法将wistar大鼠24只随机分为糖尿病组(D组)、罗格列酮治疗组(R组)和正常对照组(C组),每组8只。建立糖尿病大鼠模型1w后,R组以罗格列酮5mg·kg-1.d-1灌胃,D组和C组灌以相应量的生理盐水,8w后留取血、尿标本后处死大鼠,并留取肾脏标本做光镜和电镜观察。结果血糖水平R组和D组相近,均显著高于C组(P<0.01);但低于D组(P<0.01);光镜和电镜下R组肾小球和肾小管-肾间质病变较D组明显减轻,同C组相比仅有少量病变。结论罗格列酮可以通过活化PPAR-γ对糖尿病肾脏起到一定的保护作用,这种作用不依赖其降糖作用而独立存在,部分可能与其下调TGF-β1的表达有关。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2007年第16期1546-1547,共2页 Chinese Journal of Gerontology
基金 安徽省教育厅自然科学研究资助项目(项目编号:2006KJ318B)
作者简介 李秀财(1981-),男,硕士,从事糖尿病及其慢性并发症的研究。 通讯作者:叶山东(1964-),男,主任医师,博士,硕士生导师,从事糖尿病及其慢性并发症的研究。
  • 相关文献

参考文献8

  • 1Guan Y.Peroxisome proliferator-activated receptor family and its relationship to renal complication of the metabolic syndrome[J].J Am Soc Nephrol,2004; 15 (11):2801-15.
  • 2Bakris G,Viberti G,Weston WM,et al.Rosiglitazone reduces urinary albumin excretion in type Ⅱ diabetes[J].J Hum Hypertens,2003; 17(1):7-12.
  • 3Moraes LA,Piqueras L,Bishop D,et al.Peroxisome proliferator-activated receptors and inflammation[J].Pharmacol Ther,2005; 14 (1):2 -4.
  • 4荆春艳,叶山东,陈燕,杨明功.糖尿病患者尿转化生长因子β1检测的临床意义[J].安徽医科大学学报,2003,38(3):202-204. 被引量:5
  • 5Maeda A,Horikoshi S,Gohda T,et al.Pioglitazone attenuates TGF-beta(1)-induction of fibronection synthesis and its splicing variant in human mesangial cells via of peroxisome proliferator-activated receptor(PPAR)gamma[J].Cell Biol Int,2005 ;29(6):422-88.
  • 6Panchapakesan U,Sumual S,Pollock CA,et al.PPARγagonists exert antifibrotic effects in renal tubular cells exposed to high glucouse[J].Am J Physiol Renal Physiol,2005 ;289 (5):1153-8.
  • 7王瑞英,姚敏,王绵,苏胜偶.2型糖尿病模型大鼠肾小管上皮细胞中TGF-β1的表达及与肾功能的关系[J].中国老年学杂志,2005,25(5):549-551. 被引量:14
  • 8刘章锁,牛红心,程根阳,李军辉,宋洁.罗格列酮对糖尿病大鼠肾保护机制的研究[J].中华肾脏病杂志,2004,20(2):109-112. 被引量:35

二级参考文献39

  • 1叶山东,朱禧星.测定Ⅱ型糖尿病患者尿视黄醇结合蛋白的临床意义[J].中国糖尿病杂志,1997,5(2):93-95. 被引量:12
  • 2谢明智 刘海帆 等.实验性肥胖及糖尿病大鼠模型[J].药学学报,1985,20(11):801-801.
  • 3Sharma K, Ziyadeh FN. Hyperglycemia and diabetic. The case for transforming growth factor-beta as a key mediator. Diabetes, 1995;44(10) :1130-46.
  • 4Hoffman BB, Sharma K, Ziyadeh FN. Potential role of TGF-beta in diabetic nephropathy. Miner-Electrolyte-Metab. Kidney Int, 1998;24(2-3) :190-6.
  • 5Yamamoto T,Nohle NA,Cohen AH et al. Expression of transforming growth factor-b isoforms in human giomerular diseases.Kidney Int,1996;49(2) :461-9.
  • 6Wang SN, Lapage J, Hirschberg R et al. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int, 2000 ; 57(3) : 1002 - 14.
  • 7Wogensen L, Nielsen CB, Hjorth P et al. Under control of the Ren-1c promotor, locally produced transforming growth factorbetal induces a accumulation of glomerular extracellular matrix in transgenic mice. Diabetes, 1999 ; 48( 1 ) : 182 - 92.
  • 8Ellis D, Forrest KY, Erbey J et al. Urinary measurement of transforming growth factor-β1 and type iv collagen as new markers of renal injury: application in diabetic nephropathy Clinical Chemistry, 1998;44(5) :950-6.
  • 9Korpinen E, Teppo AM, Hukkanen Let al. Urinary transforming growth factor-beta1 and alphal-microglobulin in children and adolescents with type I diabetes. Diabetes-Care, 2000; 23(5):664-8.
  • 10Sharma K, Ziyadeh FN, Alzahabi B et al. Increased renal production of transforming growth factor-β1 in patirnts with type Ⅱ diabetes. Diabetes,1997;46(5) :854-9.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部